Comparative Pharmacology
Head-to-head clinical analysis: HEPATASOL 8 versus PREMASOL 6 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPATASOL 8 versus PREMASOL 6 IN PLASTIC CONTAINER.
HEPATASOL 8% vs PREMASOL 6% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Intravenous amino acid solution providing essential and non-essential amino acids for protein synthesis, nitrogen balance, and maintenance of lean body mass. Amino acids are actively transported into cells and incorporated into proteins; also serves as a caloric source.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
Intravenous infusion: 1 to 1.5 g/kg/day (amino acids) as part of total parenteral nutrition; typically 500 mL to 1000 mL per day, infused over 12-24 hours.
None Documented
None Documented
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Amino acids have rapid plasma clearance; elimination half-life varies from minutes to hours depending on individual amino acid; clinically, infused amino acids are cleared within 2-4 hours after infusion cessation.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Renal elimination of amino acids and metabolites; complete metabolism with nitrogen excretion as urea in urine; minimal biliary/fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution